KIAA1217 — gene · CancerIndex

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KIAA1217 Fusion2
Futibatinib	Intrahepatic Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID11611 In a phase 2 trial (NCT02052778) of the FGFR1/2/3/4 inhibitor futibatinib in 103 patients with previously treated intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, the overal… (full text at CIViC) PMID 36652354 · Goyal et al., 2023 · Open in CIViC	civic
〃	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	1	submitted	EID11647 In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC) PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

Cohorts

Alteration frequency by cohort (29)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved29 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Skin Cutaneous Melanoma (TCGA, PanCancer Atlas) skcm_tcga_pan_can_atlas_2018	Cutaneous Melanoma

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.